C4 Therapeutics, Inc. — Director's Dealing 2021

Feb 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-02-11

Reporting Person: Crystal Adam (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-11	Stock Option (Right to Buy)	$45.54	A	87850	Acquired	2031-02-10	Common Stock (87850)	Direct

Footnotes

F1: This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021.